<code id='878C1CA021'></code><style id='878C1CA021'></style>
    • <acronym id='878C1CA021'></acronym>
      <center id='878C1CA021'><center id='878C1CA021'><tfoot id='878C1CA021'></tfoot></center><abbr id='878C1CA021'><dir id='878C1CA021'><tfoot id='878C1CA021'></tfoot><noframes id='878C1CA021'>

    • <optgroup id='878C1CA021'><strike id='878C1CA021'><sup id='878C1CA021'></sup></strike><code id='878C1CA021'></code></optgroup>
        1. <b id='878C1CA021'><label id='878C1CA021'><select id='878C1CA021'><dt id='878C1CA021'><span id='878C1CA021'></span></dt></select></label></b><u id='878C1CA021'></u>
          <i id='878C1CA021'><strike id='878C1CA021'><tt id='878C1CA021'><pre id='878C1CA021'></pre></tt></strike></i>

          leisure time

          leisure time

          author:Wikipedia    Page View:25736
          James Fanale, the former CEO and president of Care New England, and his wife Deb (left) on their front porch. -- health coverage from STAT
          Courtesy Ryan Pickering

          PROVIDENCE – In late August, Dr. James E. Fanale was trudging through the Falmouth Road Race — walking up the hills, running down them — for seven miles. Fellow runners encouraged him to “keep trying” whenever he slowed down. But they couldn’t have known — along with most of the people in Fanale’s professional orbit — that he was battling Stage 4 lung cancer.

          “Many times, I wanted to say ‘Listen buddy, you don’t know what I’ve got in me,’” Fanale recalled recently with a chuckle.

          advertisement

          In December 2022, on the day Fanale retired as president and CEO of Care New England, he shared his diagnosis with a Globe reporter but requested it be kept private. He was handing the reins to new CEO Dr. Michael Wagner after six years leading the second largest health care system in Rhode Island.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more
          Acelyrin, a rare IPO success, stumbles in its first big test
          Acelyrin, a rare IPO success, stumbles in its first big test

          MarkLennihan/APThebiotechcompanyAcelyrin,whichraisedmorethan$500millioninanIPOthisyear,ranintoitsfir

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          Experts study whether long Covid risk adds up with each reinfection

          AstudyfromZiyadAl-Aly,clinicalepidemiologistatWashingtonUniversityinSt.Louis,showedthatvaccinationap